TG Therapeutics (NASDAQ:TGTX) will host a conference call on Monday, August 3, 2026 at 8:30 AM ET to discuss its second quarter 2026 financial results and provide a business outlook for the remainder of 2026, led by Chairman and CEO Michael S. Weiss.
Investors can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (international), using the conference title “TG Therapeutics Earnings Call,” or via live webcast on the Events page in the Investors & Media section of the company’s website. An audio replay will be available online for 30 days, and financial results will be released in a press statement prior to the call.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The prior first-quarter 2026 notice recorded a 0.6% 24-hour reaction. This release provided scheduli...
Analysis
The prior first-quarter 2026 notice recorded a 0.6% 24-hour reaction. This release provided scheduling information only; results and business outlook remained to be reported, with moderate short positioning a risk factor.
Key Figures
Conference Call Date:August 3, 2026Conference Call Time:8:30 AM ETAudio Replay:30 days
3 metrics
Conference Call DateAugust 3, 2026Second quarter 2026 results and business update
Conference Call Time8:30 AM ETAugust 3, 2026 conference call
Audio Replay30 daysReplay availability after the conference call
Scheduled first-quarter results call and remainder-year outlook discussion
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
All five tag-matched conference-call notices were followed by positive 24-hour price reactions.
Key Terms
multiple sclerosis, clinically isolated syndrome, relapsing-remitting disease, active secondary progressive disease, +1 more
5 terms
multiple sclerosismedical
"approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI"
A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.
A clinically isolated syndrome is a single episode of neurological symptoms caused by inflammation or damage to the insulating layer of nerves, lasting at least 24 hours and often seen as the first clear sign that a person may develop multiple sclerosis. It matters to investors because it is a clinical population and diagnostic milestone used in drug development, clinical trial design, and regulatory decisions, influencing potential market size and timelines for therapies targeting early disease stages.
relapsing-remitting diseasemedical
"clinically isolated syndrome, relapsing-remitting disease, and active secondary"
A relapsing-remitting disease is a medical condition that comes in unpredictable flare-ups of symptoms (relapses) followed by periods of partial or full recovery (remissions). For investors, this pattern matters because it affects how often patients need treatment, the size and timing of healthcare spending, and the design and goals of clinical trials and regulatory approvals, much like a seasonal business with boom-and-quiet cycles.
active secondary progressive diseasemedical
"and active secondary progressive disease, as well as approval"
A form of multiple sclerosis in which a person’s disability gradually worsens over time while also showing signs of ongoing disease activity, such as clinical relapses or new inflammatory lesions on MRI. For investors, this label identifies a specific patient population and clinical end points that influence how drugs are tested, approved, marketed, and reimbursed—think of a vehicle that is steadily breaking down but still experiences sudden, measurable breakdowns that need different repair strategies.
fdaregulatory
"approval from the U.S. Food and Drug Administration (FDA)"
The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.
Conference Call to be Held Monday, August 3, 2026, at 8:30 am ET
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by several foreign nations for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
When is TG Therapeutics (TGTX) second quarter 2026 earnings conference call?
TG Therapeutics will hold its second quarter 2026 earnings conference call on Monday, August 3, 2026 at 8:30 AM ET. According to TG Therapeutics, the call will cover Q2 2026 results and a business outlook for the remainder of 2026.
How can investors access the TG Therapeutics (TGTX) Q2 2026 earnings call?
Investors can access the TG Therapeutics Q2 2026 call by dialing 1-877-407-8029 in the U.S. or 1-201-689-8029 internationally. According to TG Therapeutics, a live webcast will also be available on the Events page of its Investors & Media website section.
Will there be a replay of the TG Therapeutics (TGTX) August 3, 2026 earnings call?
Yes, an audio recording of the August 3, 2026 TG Therapeutics earnings call will be available. According to TG Therapeutics, the replay will be hosted on www.tgtherapeutics.com for a period of 30 days following the conference call.
When will TG Therapeutics (TGTX) release Q2 2026 financial results?
TG Therapeutics will release its second quarter 2026 financial results in a press release issued prior to the August 3, 2026 call. According to TG Therapeutics, the call will then review these results and provide a business outlook for 2026.
How can investors listen to the TG Therapeutics (TGTX) earnings webcast online?
Investors can listen to the earnings webcast live via the Events page in the Investors & Media section of www.tgtherapeutics.com. According to TG Therapeutics, the webcast will cover Q2 2026 results and management’s business update.
Who will host the TG Therapeutics (TGTX) Q2 2026 earnings conference call?
The TG Therapeutics Q2 2026 earnings conference call will be hosted by Michael S. Weiss, Chairman and Chief Executive Officer. According to TG Therapeutics, he will discuss quarterly financial results and the company’s business outlook for the remainder of 2026.
